Erik Cederfjäll, Ph.D.
|2008-2014||B.R.A.I.N.S. Unit||Lund University, Lund, Skåne län, Sweden|
|2015-2017||Molecules - Signaling - Development||Max Planck Institute of Neurobiology, Jupiter, FL, United States|
Area:Parkinson's disease | Gene therapy
Mean distance: 17.38 (cluster 11)
ParentsSign in to add mentor
ChildrenSign in to add trainee
BETA: Related publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
|Cederfjäll E, Broom L, Kirik D. (2015) Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 896-906|
|CederfjÃ¤ll E, Nilsson N, Sahin G, et al. (2013) Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Scientific Reports. 3: 2157|
|CederfjÃ¤ll E, Sahin G, Kirik D, et al. (2012) Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 1315-26|
|CederfjÃ¤ll E, Sahin G, Kirik D. (2012) Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain. Neurobiology of Disease. 48: 222-7|
|BjÃ¶rklund T, CederfjÃ¤ll EA, Kirik D. (2010) Gene therapy for dopamine replacement. Progress in Brain Research. 184: 221-35|
|BjÃ¶rklund T, Carlsson T, CederfjÃ¤ll EA, et al. (2010) Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain : a Journal of Neurology. 133: 496-511|